CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 18:43 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 16:36 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
December 11, 2022 10:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022 17:49 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
October 04, 2022 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
August 15, 2022 07:15 ET
|
Gracell Biotechnologies Inc.
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which...
Monthly information on share capital and company voting rights
May 10, 2022 16:43 ET
|
Cellectis Inc.
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
April 04, 2022 06:00 ET
|
Tessa Therapeutics Ltd
SINGAPORE, April 04, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...